$35.51
1.15% yesterday
Nasdaq, Aug 01, 10:00 pm CET

Supernus Pharmaceuticals, Inc. Stock price

$35.51
+3.69 11.58% 1M
-1.86 4.97% 6M
-0.66 1.81% YTD
+5.94 20.07% 1Y
+4.01 12.71% 3Y
+12.22 52.45% 5Y
+14.41 68.27% 10Y
+30.14 561.17% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.41 1.15%

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.5b
Net debt
positive
Cash
$463.6m
Shares outstanding
56.0m
Valuation (TTM | estimate)
P/E
32.3 | 20.5
P/S
3.0 | 3.0
EV/Sales
2.3 | 2.3
EV/FCF
9.3
P/B
1.9
Financial Health
Equity Ratio
75.7%
Return on Equity
7.1%
ROCE
7.0%
ROIC
6.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$668.0m | $653.9m
EBITDA
$152.2m | $218.3m
EBIT
$74.6m | $128.8m
Net Income
$61.9m | $96.9m
Free Cash Flow
$163.4m
Growth (TTM | estimate)
Revenue
11.8% | -1.2%
EBITDA
121.0% | 29.5%
EBIT
646.3% | 42.2%
Net Income
499.4% | 31.2%
Free Cash Flow
63.5%
Margin (TTM | estimate)
Gross
89.8%
EBITDA
22.8% | 33.4%
EBIT
11.2%
Net
9.3% | 14.8%
Free Cash Flow
24.5%
More
EPS
$1.1
FCF per Share
$2.9
Short interest
13.0%
Employees
674
Rev per Employee
$980.0k
Show more

Is Supernus Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Supernus Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:

Buy
64%
Hold
36%

Financial data from Supernus Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
668 668
12% 12%
100%
- Direct Costs 68 68
11% 11%
10%
600 600
15% 15%
90%
- Selling and Administrative Expenses 325 325
4% 4%
49%
- Research and Development Expense 111 111
16% 16%
17%
152 152
121% 121%
23%
- Depreciation and Amortization 78 78
6% 6%
12%
EBIT (Operating Income) EBIT 75 75
646% 646%
11%
Net Profit 62 62
499% 499%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Supernus Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Supernus Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial produc...
Neutral
GlobeNewsWire
5 days ago
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: ...
Neutral
GlobeNewsWire
11 days ago
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.
More Supernus Pharmaceuticals, Inc. News

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Head office United States
CEO Jack Khattar
Employees 674
Founded 2005
Website www.supernus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today